News Releases | Investor Relations | Alpine Immune Sciences

October 27, 2015

Summary Toggle Kite and Alpine Immune Sciences collaborate to improve engineered cellular therapies

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment ‐ Kite to Exclusively License Transmembrane Immunomodulatory Protein Technology for Applications to CAR and TCR Programs SANTA MONICA, Calif.
Read More
March 1, 2015

Summary Toggle Why ex-Dendreon CEO's new biotech startup could succeed where Dendreon failed

As former CEO of Seattle biotech Dendreon Corp. Mitchell Gold embarks on a new biotech immunotherapy company called Alpine Immune Sciences Inc. , how will he ensure it doesn’t meet the same fate as his prior company? Gold led Dendreon for nine years and stepped down in 2012.
Read More
February 1, 2015

Summary Toggle Former Dendreon CEO launches stealth next-gen immunotherapy startup in Seattle

Dendreon may be on its last legs , but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences , seeding about $1.3 million into the company through his investment firm, Alpine BioVentures .
Read More